Chapter 21 – Amrita: The First Cure
March 2010 – Dehradun, India
Ram stood silently by the edge of his grandmother's bed.
The woman who had raised him, held him close when he woke from nightmares, told him stories of gods and heroes, now lay weak, her eyes dimmed with fatigue. The diagnosis had been cruel and swift—late-stage liver fibrosis. In his original timeline, she had passed around this time.
But this time, he was not helpless.
He had the power of Athena. The wealth of hidden billions. The knowledge of 2025.
And this time, he would not let her die.
---
A Promise Made in Silence
Ram didn't cry.
Instead, he sat beside her that night, holding her hand, letting her fall asleep while Athena silently ran a full-body biometric analysis using a disguised medical scanner embedded in Ram's wristband.
Within seconds, Athena's voice spoke quietly in his neural link.
> "Prognosis: 3 to 6 months without intervention. Standard therapy: supportive. Probability of survival beyond 1 year: 12.4%. Suggest activating contingency protocol 'Amrita.'"
Ram replied without hesitation:
> "Do it. Build everything."
And thus, Amrita Biotech was born.
---
The Hidden Lab
Within days, land was purchased in the outskirts of Haridwar through a fake trust—ostensibly for spiritual retreat development. Underground, a lab began taking shape—built in secret by Dyads, disguised as well-funded yoga research centers.
Named after the mythical elixir of immortality, Amrita Biotech would do what no pharma company dared to:
Use knowledge from the future to recreate cures no one had invented yet.
---
Building the Cure
Athena reconstructed a gene therapy protocol that had only begun early-stage human trials in 2023. It used CRISPRv3, engineered viral vectors, and nano-scale delivery capsules—technology completely foreign to 2010 science.
Ram knew he couldn't release the full cure publicly—it would expose his secret.
But for his grandmother, he would risk anything.
With stealth biochemists hired under false pretenses, AI-modeled protein folding simulations, and custom-made synthesis machines hidden in the lab, the first doses were developed by early April.
---
The First Trial
Ram held the syringe with steady hands.
His grandmother, frail but smiling, whispered:
> "Beta, what is this? Why all this fuss for an old woman?"
He kissed her hand.
> "It's just vitamins, Daadi. But from the future."
The serum entered her bloodstream. Within a week, her appetite returned. Within two, her color improved. By the end of the month, her liver enzyme profile reversed, shocking the local doctor.
By May, she was walking again—laughing, tending to the garden, unaware she had just survived a disease considered fatal by 2010 standards.
---
Scaling Up
Ram knew this was bigger than one life.
There were millions of people like his grandmother—poor, ignored, and dying from treatable illnesses. So he made a bold decision: Amrita Biotech would become a shadow pharma empire, not to profit, but to cure.
Key elements:
Generic medicine factories in Jharkhand and Odisha disguised as "community health initiatives"
Distributed R&D teams working on Alzheimer's, diabetes, malaria, and tuberculosis under open research licenses
AI-aided diagnosis tools given to his NGO clinics, disguised as "school health checks"
All free. All anonymous. All powered by Athena.
---
Ram's Journal – March 29, 2010
> "This was never about money.
This is about rewriting fate.
The future is not a straight line—it's a codebase.
And I'm the one holding the root access now."
---
By the Numbers – March 2010
Company Launched: Amrita Biotech (secret ownership)
Main Facility: Haridwar, Uttarakhand (underground)
Flagship Cure: Gen-T3 Liver Repair Serum (cured 1 subject)
Distributed Clinics: 12 (run under Saraswati NGO umbrella)
Hidden Pharma Tech Level: Equivalent to 2024 Western standards
---
Ram had created something far greater than a medicine company.
He had created hope—engineered in silence, powered by love.
And this was only the beginning.
---
End of Chapter 21